Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway.
Apoptosis
/ physiology
Carbon-Nitrogen Lyases
/ metabolism
Cell Line, Tumor
Cell Proliferation
/ physiology
Humans
Pancreatic Neoplasms
/ metabolism
Phosphatidylinositol 3-Kinases
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Signal Transduction
/ physiology
TOR Serine-Threonine Kinases
/ metabolism
AKT
Desumoylating isopeptidase 2
Pancreatic cancer
Phosphatidylinositide 3-kinases
mTOR
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
02
08
2018
accepted:
09
10
2018
pubmed:
10
11
2018
medline:
14
6
2019
entrez:
10
11
2018
Statut:
ppublish
Résumé
This study aimed to investigate the effects of desumoylating isopeptidase 2 (DESI2) on tumor cell proliferation, apoptosis and invasion of pancreatic cancer, and to assess the signaling pathway involved. Overexpression and silence of DESI2 were designed and the experiments were divided into 5 groups: a normal control group, an interference control group (shRNA-NC); an interference group (sh-DESI2); an overexpression control group (NC), an overexpression group (DESI2). Quantitative real time polymerase chain reaction (qRT-PCR) was used to screen the appropriate interference sequence. The silencing and overexpression of DESI2 were confirmed by qRT-PCR and western blotting. Cell cycling, apoptosis, invasion, and the expression of phosphatidylinositol-3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway and caspase 3 were measured. Overexpression and silence of DESI2 were successfully designed in two pancreatic cancer cells, and the interference effect of sh-DESI2-3 showed the best silencing effects. The biological activities of DESI2 were detected in both ASPC-1 and PANCE-1 cells. Our results showed that cell proliferation was significantly increased in the sh-DESI2 group, while decreased in DESI2 group compared with the control group in both cell lines. In ASPC-1 cells, the events in G1 phase decreased and in S phase increased obviously in the sh-DESI2 group, compared with control group. An opposite result was found when DESI2 was overexpressed. In PANCE-1 cells, the events in G2 phase were higher in the sh-DESI2 group, while in the DESI2 group was significantly lower than that in control group. In ASPC-1 and PANCE-1 cells, sh-DESI2 group showed decreased apoptosis, increased cell invasion and increased expression of AKT, p-Akt, PI3K, p-PI3K, p-mTOR and mTOR and decreased caspase 3 expression compared with the control group, while overexpression of DESI2 leaded to increased apoptosis, decreased cell invasion and reduced expression of AKT, p-Akt, PI3K, p-PI3K, p-mTOR and mTOR and increased expression of caspase 3. DESI2 regulates the proliferation and apoptosis of pancreatic cancer cells through PI3K/AKT/mTOR signaling pathway.
Identifiants
pubmed: 30411297
doi: 10.1007/s12253-018-0487-4
pii: 10.1007/s12253-018-0487-4
doi:
Substances chimiques
MTOR protein, human
EC 2.7.1.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Carbon-Nitrogen Lyases
EC 4.3.-
DESI2 protein, human
EC 4.3.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
635-646Références
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903
pubmed: 12477932
Am J Physiol Cell Physiol. 2004 Aug;287(2):C281-91
pubmed: 15028555
Cell Biol Int. 2009 Mar;33(3):276-82
pubmed: 19101642
Biochimie. 2009 Apr;91(4):502-7
pubmed: 19133312
Cancer Chemother Pharmacol. 2009 Dec;65(1):13-25
pubmed: 19387645
Cancer Sci. 2009 Sep;100(9):1757-66
pubmed: 19575751
J Biomed Biotechnol. 2010;2010:134764
pubmed: 20454583
J Mol Signal. 2010 Jul 19;5:10
pubmed: 20642839
Oncol Rep. 2011 Sep;26(3):703-10
pubmed: 21667029
Clin Cancer Res. 2012 Apr 15;18(8):2316-25
pubmed: 22261800
Neurochem Int. 2012 Mar;60(4):400-8
pubmed: 22265823
J Clin Oncol. 2012 Mar 10;30(8):777-82
pubmed: 22271473
Oncol Rep. 2012 Aug;28(2):501-10
pubmed: 22641480
Apoptosis. 2013 Apr;18(4):467-79
pubmed: 23322088
Virchows Arch. 2013 Apr;462(4):429-36
pubmed: 23443941
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Br J Cancer. 2014 Aug 26;111(5):817-22
pubmed: 24755884
Pathol Oncol Res. 2015 Apr;21(2):267-72
pubmed: 25079376
J Neurosci. 2015 Jan 14;35(2):621-33
pubmed: 25589756
Naunyn Schmiedebergs Arch Pharmacol. 2015 Jun;388(6):623-34
pubmed: 25743573
J Biol Chem. 2015 Jun 12;290(24):14927-44
pubmed: 25918161
Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1317-26
pubmed: 26399781
Cancer Res. 2016 Jan 15;76(2):227-38
pubmed: 26637667
Oncotarget. 2016 Feb 23;7(8):9135-49
pubmed: 26824320
Oncotarget. 2016 Feb 23;7(8):9586-99
pubmed: 26840020
Cell Death Dis. 2016 Feb 04;7:e2087
pubmed: 26844701
Res Vet Sci. 2016 Apr;105:124-33
pubmed: 27033920
Avicenna J Med Biotechnol. 2016 Apr-Jun;8(2):75-83
pubmed: 27141266
Mol Cell Oncol. 2014 Oct 29;1(3):e963447
pubmed: 27308344
Oncotarget. 2016 Nov 22;7(47):77916-77925
pubmed: 27788491
Mol Med Rep. 2017 May;15(5):3259-3263
pubmed: 28339041
J Exp Clin Cancer Res. 2017 Sep 11;36(1):124
pubmed: 28893319
Oncotarget. 2017 May 5;8(34):56281-56295
pubmed: 28915590
Oncotarget. 2017 Sep 27;8(50):87997-88007
pubmed: 29152136